Hubei Biocause Pharmaceutical (000627) — Strategic Asset Allocation Index
Hubei Biocause Pharmaceutical (000627) has a Strategic Asset Allocation Index of 368.8% as of September 2024. Strategic assets (PP&E of CN¥- plus long-term investments of CN¥132.77 Billion) total CN¥132.77 Billion, measured against net assets of CN¥36.00 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Hubei Biocause Pharmaceutical asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Hubei Biocause Pharmaceutical Strategic Asset Allocation Index (2000–2023)
This chart shows how Hubei Biocause Pharmaceutical's Strategic Asset Allocation Index has evolved across 24 annual periods from 2000 to 2023. As of September 2024, the index stands at 368.8%, representing strategic assets of CN¥132.77 Billion against net assets of CN¥36.00 Billion CNY. See 000627 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Hubei Biocause Pharmaceutical (2000–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 000627 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 408.8% | CN¥137.49 Billion | CN¥- | CN¥137.49 Billion | CN¥33.63 Billion | ▲ +21.8 pp |
| 2022 | 387.0% | CN¥133.91 Billion | CN¥- | CN¥133.91 Billion | CN¥34.60 Billion | ▲ +66.8 pp |
| 2021 | 320.2% | CN¥120.00 Billion | CN¥830.33 Million | CN¥119.17 Billion | CN¥37.47 Billion | ▲ +282.7 pp |
| 2020 | 37.5% | CN¥12.97 Billion | CN¥580.44 Million | CN¥12.39 Billion | CN¥34.59 Billion | ▼ -2.3 pp |
| 2019 | 39.8% | CN¥13.66 Billion | CN¥567.17 Million | CN¥13.10 Billion | CN¥34.35 Billion | ▼ -259.0 pp |
| 2018 | 298.8% | CN¥77.73 Billion | CN¥770.87 Million | CN¥76.96 Billion | CN¥26.01 Billion | ▲ +63.6 pp |
| 2017 | 235.2% | CN¥62.82 Billion | CN¥700.40 Million | CN¥62.12 Billion | CN¥26.70 Billion | ▼ -81.7 pp |
| 2016 | 316.9% | CN¥64.64 Billion | CN¥587.41 Million | CN¥64.05 Billion | CN¥20.40 Billion | ▲ +233.1 pp |
| 2015 | 83.8% | CN¥1.50 Billion | CN¥334.69 Million | CN¥1.16 Billion | CN¥1.78 Billion | ▲ +53.3 pp |
| 2014 | 30.5% | CN¥454.18 Million | CN¥454.18 Million | CN¥- | CN¥1.49 Billion | ▼ -36.9 pp |
| 2013 | 67.3% | CN¥967.21 Million | CN¥967.21 Million | CN¥- | CN¥1.44 Billion | ▲ +5.1 pp |
| 2012 | 62.2% | CN¥956.70 Million | CN¥956.70 Million | CN¥- | CN¥1.54 Billion | ▲ +4.8 pp |
| 2011 | 57.4% | CN¥811.97 Million | CN¥811.97 Million | CN¥- | CN¥1.41 Billion | ▲ +0.6 pp |
| 2010 | 56.8% | CN¥909.50 Million | CN¥909.50 Million | CN¥- | CN¥1.60 Billion | ▼ -15.0 pp |
| 2009 | 71.8% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥1.57 Billion | ▲ +12.6 pp |
| 2008 | 59.2% | CN¥895.44 Million | CN¥895.44 Million | CN¥- | CN¥1.51 Billion | ▼ -14.1 pp |
| 2007 | 73.3% | CN¥634.63 Million | CN¥634.63 Million | CN¥- | CN¥866.03 Million | ▼ -3.7 pp |
| 2006 | 77.0% | CN¥557.14 Million | CN¥557.14 Million | CN¥- | CN¥723.71 Million | ▲ +10.7 pp |
| 2005 | 66.3% | CN¥484.56 Million | CN¥484.56 Million | CN¥- | CN¥731.23 Million | ▲ +18.8 pp |
| 2004 | 47.4% | CN¥343.27 Million | CN¥343.27 Million | CN¥- | CN¥723.91 Million | ▲ +0.3 pp |
| 2003 | 47.1% | CN¥338.44 Million | CN¥338.44 Million | CN¥- | CN¥718.75 Million | ▲ +5.1 pp |
| 2002 | 42.0% | CN¥322.21 Million | CN¥322.21 Million | CN¥- | CN¥768.02 Million | ▲ +7.5 pp |
| 2001 | 34.5% | CN¥262.88 Million | CN¥262.88 Million | CN¥- | CN¥762.99 Million | ▼ -25.3 pp |
| 2000 | 59.7% | CN¥355.08 Million | CN¥355.08 Million | CN¥- | CN¥594.52 Million | — |